Langerhans cell histiocytosis pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:
{{CMG}}; {{AE}} {{HL}}
{{CMG}}; {{AE}} {{HL}}
==Overview==
==Overview==
Langerhans cell histiocytosis arises from [[epidermis|epidermal]] [[dendritic cell]]s, which are normally involved in the process of [[antigen]] presentation to [[lymphocyte|lymphocytic cell]]s. Langerhans cells originally arise from the [[bone marrow]], then the cells migrate to other organs such as the [[skin]], [[lymph node]]s, and [[lung]]s. The exact pathogenesis of Langerhans cell histiocytosis is not fully understood. It is thought that Langerhans cell histiocytosis is the result of either a true [[neoplastic]] process or a reactive [[immune]] condition. [[Gene]]s commonly involved in the pathogenesis of Langerhans cell histiocytosis include [[BRAF]] gene and MAP2K1 gene. On gross pathology, scaly [[erythema]], red [[papule]]s, and extensive eruptions located on the [[scalp]] are characteristic finding of Langerhans cell histiocytosis. Characteristic findings of Langerhans cell histiocytosis on light microscopy may include clusters of dendritic cells with kidney-shaped [[nucleus]] and abundant foamy [[cytoplasm]]. On electron microscopy Langerhans cell histiocytosis is characterized by Birbeck granules, which are electron dense, cytoplasmic, tennis racket-like bodies. On immunohistochemistry Langerhans cell histiocytosis is characterized by positivity to [[CD1a]], S100, and CD207 (langerin).<ref name="pmid25281259">{{cite journal| author=DiCaprio MR, Roberts TT| title=Diagnosis and Management of Langerhans Cell Histiocytosis. | journal=J Am Acad Orthop Surg | year= 2014 | volume= 22 | issue= 10 | pages= 643-652 | pmid=25281259 | doi=10.5435/JAAOS-22-10-643 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25281259  }} </ref><ref name="pmid25310214">{{cite journal| author=Grana N| title=Langerhans cell histiocytosis. | journal=Cancer Control | year= 2014 | volume= 21 | issue= 4 | pages= 328-34 | pmid=25310214 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25310214  }} </ref><ref name="pmid26414464">{{cite journal| author=Harmon CM, Brown N| title=Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update. | journal=Arch Pathol Lab Med | year= 2015 | volume= 139 | issue= 10 | pages= 1211-4 | pmid=26414464 | doi=10.5858/arpa.2015-0199-RA | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26414464  }} </ref><ref name="wiki">Langerhans cell histiocytosis. Wikipedia (2015) https://en.wikipedia.org/wiki/Langerhans_cell_histiocytosis Accessed on February, 2 2016</ref>
Langerhans cell histiocytosis arises from [[epidermis|epidermal]] [[dendritic cell]]s, which are normally involved in the process of [[antigen]] presentation to [[lymphocyte|lymphocytic cell]]s. Langerhans cells originally arise from the [[bone marrow]], then the cells migrate to other organs such as the [[skin]], [[lymph node]]s, and [[lung]]s. The exact pathogenesis of Langerhans cell histiocytosis is not fully understood. It is thought that Langerhans cell histiocytosis is the result of either a true [[neoplastic]] process or a reactive [[immune]] condition. [[Gene]]s commonly involved in the pathogenesis of Langerhans cell histiocytosis include [[BRAF]] gene and MAP2K1 gene. On gross pathology, scaly [[erythema]], red [[papule]]s, and extensive eruptions located on the [[scalp]] are characteristic finding of Langerhans cell histiocytosis. Characteristic findings of Langerhans cell histiocytosis on light microscopy may include clusters of dendritic cells with kidney-shaped [[nucleus]] and abundant foamy [[cytoplasm]]. On electron microscopy Langerhans cell histiocytosis is characterized by Birbeck granules, which are electron dense, cytoplasmic, tennis racket-like bodies. On immunohistochemistry Langerhans cell histiocytosis is characterized by positivity to [[CD1a]], S100, and CD207 (langerin).<ref name="pmid25281259">{{cite journal| author=DiCaprio MR, Roberts TT| title=Diagnosis and Management of Langerhans Cell Histiocytosis. | journal=J Am Acad Orthop Surg | year= 2014 | volume= 22 | issue= 10 | pages= 643-652 | pmid=25281259 | doi=10.5435/JAAOS-22-10-643 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25281259  }} </ref><ref name="pmid25310214">{{cite journal| author=Grana N| title=Langerhans cell histiocytosis. | journal=Cancer Control | year= 2014 | volume= 21 | issue= 4 | pages= 328-34 | pmid=25310214 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25310214  }} </ref><ref name="pmid26414464">{{cite journal| author=Harmon CM, Brown N| title=Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update. | journal=Arch Pathol Lab Med | year= 2015 | volume= 139 | issue= 10 | pages= 1211-4 | pmid=26414464 | doi=10.5858/arpa.2015-0199-RA | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26414464  }} </ref><ref name="PDQ">Langerhans Cell Histiocytosis Treatment (PDQ®): Health Professional Version.  National Cancer Institute (2015) http://www.cancer.gov/types/langerhans/hp/langerhans-treatment-pdq Accessed on February, 3 2016</ref><ref name="wiki">Langerhans cell histiocytosis. Wikipedia (2015) https://en.wikipedia.org/wiki/Langerhans_cell_histiocytosis Accessed on February, 2 2016</ref>
==Pathogenesis==  
==Pathogenesis==  
* Langerhans cell histiocytosis arises from [[epidermis|epidermal]] [[dendritic cell]]s, which are normally involved in the process of [[antigen]] presentation to [[lymphocyte|lymphocytic cell]]s.
* Langerhans cell histiocytosis arises from [[epidermis|epidermal]] [[dendritic cell]]s, which are normally involved in the process of [[antigen]] presentation to [[lymphocyte|lymphocytic cell]]s.

Revision as of 12:30, 3 February 2016

Langerhans cell histiocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Langerhans cell histiocytosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Langerhans cell histiocytosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Langerhans cell histiocytosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Langerhans cell histiocytosis pathophysiology

on Langerhans cell histiocytosis pathophysiology

Langerhans cell histiocytosis pathophysiology in the news

Blogs on Langerhans cell histiocytosis pathophysiology

Directions to Hospitals Treating Langerhans cell histiocytosis

Risk calculators and risk factors for Langerhans cell histiocytosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]

Overview

Langerhans cell histiocytosis arises from epidermal dendritic cells, which are normally involved in the process of antigen presentation to lymphocytic cells. Langerhans cells originally arise from the bone marrow, then the cells migrate to other organs such as the skin, lymph nodes, and lungs. The exact pathogenesis of Langerhans cell histiocytosis is not fully understood. It is thought that Langerhans cell histiocytosis is the result of either a true neoplastic process or a reactive immune condition. Genes commonly involved in the pathogenesis of Langerhans cell histiocytosis include BRAF gene and MAP2K1 gene. On gross pathology, scaly erythema, red papules, and extensive eruptions located on the scalp are characteristic finding of Langerhans cell histiocytosis. Characteristic findings of Langerhans cell histiocytosis on light microscopy may include clusters of dendritic cells with kidney-shaped nucleus and abundant foamy cytoplasm. On electron microscopy Langerhans cell histiocytosis is characterized by Birbeck granules, which are electron dense, cytoplasmic, tennis racket-like bodies. On immunohistochemistry Langerhans cell histiocytosis is characterized by positivity to CD1a, S100, and CD207 (langerin).[1][2][3][4][5]

Pathogenesis

  • Organ involvement is variable among patients with Langerhans cell histiocytosis. The disease process may range from an isolated cutaneous or bone involvement to a life-threatening multi-system condition.
  • The skeletal distribution of Langerhans cell histiocytosis involves the following sites:
  • The exact pathogenesis of Langerhans cell histiocytosis is not fully understood. It is thought that Langerhans cell histiocytosis is the result of either a true neoplastic process or a reactive immune condition.
  • Facts consistent with the neoplastic process hypothesis include the following:
  • The infiltration of organs by monoclonal population of pathologic cells
  • The presence of specific recurrent cytogenetic and genomic abnormalities
  • The successful treatment of a subset of disseminated Langerhans cell histiocytosis using chemotherapeutic regimens
  • Facts consistent with the reactive immune condition hypothesis include the following:
  • The evidence of spontaneous remissions that may occur among certain cases of Langerhans cell histiocytosis
  • The extensive secretion of multiple cytokines by dendritic cells and bystander-cells (a phenomenon known as cytokine storm)
  • The favorable prognosis and relatively good survival rate among patients with no organ dysfunction
  • The uncontrolled monoclonal proliferation of Langerhans cells will initiate a non-specific inflammatory response, which will lead to the accumulation of various immune system cells such as:
  • Langerhans cell histiocytosis may result in bone marrow failure due to malignant cell infiltration of the bone marrow. This can manifest as:
  • The infiltration of the hypothalamic-pituitary axis by Langerhans cells will lead to a deficiency in both anterior and posterior pituitary hormones, which may result in:

Genetics

  • Development of Langerhans cell histiocytosis is the result of multiple genetic mutations.
  • Genes commonly involved in the pathogenesis of Langerhans cell histiocytosis include:

Associated Conditions

  • Langerhans cell histiocytosis is associated with a number of syndromes that include:

Gross Pathology

  • On gross pathology, scaly erythema, red papules, and extensive eruptions located on the scalp are characteristic finding of Langerhans cell histiocytosis.
  • The image below demonstrates the cutaneous scalp lesions observed among Langerhans cell histiocytosis patients:

Microscopic Pathology

  • Characteristic findings of Langerhans cell histiocytosis on light microscopy may include:
  • On electron microscopy Langerhans cell histiocytosis is characterized by Birbeck granules, which are electron dense, cytoplasmic, tennis racket-like bodies.
  • On immunohistochemistry Langerhans cell histiocytosis is characterized by:
  • CD1a +ve
  • S100 +ve
  • CD207 (langerin) +ve

Gallery

Illustrated below is a series of microscopic images demonstrating Langerhans cell histiocytosis:

References

  1. DiCaprio MR, Roberts TT (2014). "Diagnosis and Management of Langerhans Cell Histiocytosis". J Am Acad Orthop Surg. 22 (10): 643–652. doi:10.5435/JAAOS-22-10-643. PMID 25281259.
  2. Grana N (2014). "Langerhans cell histiocytosis". Cancer Control. 21 (4): 328–34. PMID 25310214.
  3. Harmon CM, Brown N (2015). "Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update". Arch Pathol Lab Med. 139 (10): 1211–4. doi:10.5858/arpa.2015-0199-RA. PMID 26414464.
  4. Langerhans Cell Histiocytosis Treatment (PDQ®): Health Professional Version. National Cancer Institute (2015) http://www.cancer.gov/types/langerhans/hp/langerhans-treatment-pdq Accessed on February, 3 2016
  5. Langerhans cell histiocytosis. Wikipedia (2015) https://en.wikipedia.org/wiki/Langerhans_cell_histiocytosis Accessed on February, 2 2016


Template:WikiDoc Sources